Know Cancer

or
forgot password

SCORAD: A Randomised Feasibility Study of Single Fraction Radiotherapy Compared to Multi-Fraction Radiotherapy in Patients With Metastatic Spinal Cord Compression


N/A
18 Years
N/A
Open (Enrolling)
Both
Spinal Cord Compression, Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

SCORAD: A Randomised Feasibility Study of Single Fraction Radiotherapy Compared to Multi-Fraction Radiotherapy in Patients With Metastatic Spinal Cord Compression


OBJECTIVES:

- To examine whether a phase III randomized study comparing a single-fraction of
radiotherapy with multi-fraction radiotherapy is acceptable to clinicians and to
patients with metastatic spinal cord compression.

- To determine the feasibility of conducting this study in the United Kingdom.

OUTLINE: This is a multicenter study. Patients are stratified by treatment center and known
prognostic factors (ambulatory status at diagnosis, primary tumor type, and extent of
disease [spinal metastases only vs spinal and non-bony metastases]). Patients are randomized
to 1 of 2 treatment arms.

- Arm I (multi-fraction radiotherapy): Patients undergo 5 fractions of 20 Gy
external-beam radiotherapy.

- Arm II (single-fraction radiotherapy): Patients undergo 1 fraction of 8 Gy external
beam radiotherapy.

Patients undergo assessment of ambulatory status, quality of life, bladder and bowel
function, and acute toxicity via self-reported questionnaires and telephone follow-ups at
baseline and weeks 1, 4, 8, and 12.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed malignant disease

- Proven diagnosis of metastatic spinal cord compression on MRI or CT scan

- Single site of compression OR multiple sites that can be treated within a single
radiation treatment field

- No patient for whom surgery or chemotherapy treatment is more appropriate

- No multiple myeloma as primary cancer

PATIENT CHARACTERISTICS:

- Life expectancy > 1 month

- Not pregnant

- Willing and able to complete assessment forms

- Able to give informed consent

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Primary Purpose: Treatment

Outcome Measure:

Patient accrual per center over a 12-month period

Safety Issue:

No

Principal Investigator

Peter J. Hoskin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Vernon Cancer Centre at Mount Vernon Hospital

Authority:

Unspecified

Study ID:

CDR0000599886

NCT ID:

NCT00727584

Start Date:

November 2007

Completion Date:

Related Keywords:

  • Spinal Cord Compression
  • Unspecified Adult Solid Tumor, Protocol Specific
  • spinal cord compression
  • unspecified adult solid tumor, protocol specific
  • Spinal Cord Compression

Name

Location